RecruitingRecruiting
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
NCT07868835 · Viking Therapeutics, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
About this study
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults who are obese or overweight with one or more weight related comorbid conditions without Type 2 Diabetes Mellitus.
Eligibility criteria
Inclusion Criteria:
1. Age ≥18 years of age at the time of signing the informed consent.
2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).
* Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
* Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.
* BMI calculated at the screening visit will be used to determine eligibility.
Exclusion Criteria:
1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy
6. Treatment with glucose-lowering agent(s) within 90 days before screening
7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
8. History of acute or chronic pancreatitis
Study design
Enrollment target: 560 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-11
Estimated completion: 2028-08
Last updated: 2026-11-16
Interventions
Drug: VK2735Drug: Placebo comparator
Primary outcomes
- • Percentage change in body weight for participants receiving VK2735 orally once daily (68 weeks)
Sponsor
Viking Therapeutics, Inc. · industry
Contacts & investigators
ContactHubert Chen, MD · contact · clinicaltrials@vikingtherapeutics.com · 8587044660
All locations (20)
Viking Clinical Site #1020Recruiting
Tucson, Arizona, United States
Viking Clinical Site #1018Recruiting
Chula Vista, California, United States
Viking Clinical Site #1015Recruiting
Lake Forest, California, United States
Viking Clinical Site #1005Recruiting
Melbourne, Florida, United States
Viking Clinical Site #1003Recruiting
The Villages, Florida, United States
Viking Clinical Site #1013Recruiting
Atlanta, Georgia, United States
Viking Clinical Site #1001Recruiting
Evansville, Indiana, United States
Viking Clinical Site #1009Recruiting
Valparaiso, Indiana, United States
Viking Clinical Site #1014Recruiting
Louisville, Kentucky, United States
Viking Clinical Site #1004Recruiting
Richfield, Minnesota, United States
Viking Clinical Site #1029Recruiting
Jackson, Mississippi, United States
Viking Clinical Site #1028Recruiting
Springfield, Missouri, United States
Viking Clinical Site #1006Recruiting
Rochester, New York, United States
Viking Clinical Site #1035Recruiting
Morehead City, North Carolina, United States
Viking Clinical Site #1023Recruiting
Medford, Oregon, United States
Viking Clinical Site #1002Recruiting
East Greenwich, Rhode Island, United States
Viking Clinical Site #1030Recruiting
Henderson, Tennessee, United States
Viking Clinical Site #1031Recruiting
Abilene, Texas, United States
Viking Clinical Site #1026Recruiting
Salt Lake City, Utah, United States
Viking Clinical Site #1011Recruiting
Seattle, Washington, United States